COP1 is downregulated in renal cell carcinoma (RCC) and inhibits the migration of RCC ACHN cells in vitro

Ta,La; Xuan,Chengrui; Xing,Nianzeng; Zhu,Xiaojun

doi:10.3892/mmr.2016.5373

COP1 is downregulated in renal cell carcinoma (RCC) and inhibits the migration of RCC ACHN cells in vitro

Authors:
- La Ta
- Chengrui Xuan
- Nianzeng Xing
- Xiaojun Zhu
View Affiliations

Affiliations: Department of Urology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, P.R. China, Department of Pathophysiology, Inner Mongolia Medical University, Hohhot, Inner Mongolia 010110, P.R. China, Department of Urology, The First Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia 010059, P.R. China
Published online on: June 7, 2016 https://doi.org/10.3892/mmr.2016.5373
Pages: 1371-1378

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Constitutive photomorphogenic 1 (COP1) belongs to the COP‑de-etiolated (DET)‑fusca (FUS) protein family and has been demonstrated to suppress prostate adenocarcinomas and other types of tumor, such as liver and gastric cancer. The present study investigated the expression of COP1 and its downstream factor, ets variant 1 (ETV1) in renal cell carcinoma (RCC) tissue samples, and evaluated the correlation of COP1 expression levels with the clinicopathological characteristics of RCC. In addition, the role of COP1 in the proliferation and migration of RCC ACHN cells was investigated. The results demonstrated significantly downregulated COP1 expression levels in the RCC intratumors, which was negatively associated with clinicopathological characteristics, such as tumor size, tumor‑node‑metastasis (TNM) stage and lymph node or distant metastasis. COP1 was demonstrated to markedly reduce the colony size of RCC ACHN cells, and inhibit the migration and invasion of ACHN cells. In addition, ETV1 and matrix metalloproteinase 7 (MMP7) mRNA and protein expression levels were significantly downregulated by the overexpressed COP1. Thus, the results of the present study demonstrate the reduced expression of COP1 and the upregulated expression of ETV1 in RCC tissue samples, which was associated with a high tumor-node-metastasis stage of RCC. Furthermore, the overexpression of COP1 in the RCC ACHN cells inhibited the migration and invasion of ACHN cells, and downregulated ETV1 and MMP7 expression levels. The present study demonstrated the tumor suppressive role of COP1 in RCC by inhibiting cell migration.

View Figures

View References

1	Rini BI, Campbell SC and Escudier B: Renal cell carcinoma. Lancet. 373:1119–1132. 2009. View Article : Google Scholar : PubMed/NCBI
2	Rini BI, Rathmell WK and Godley P: Renal cell carcinoma. Curr Opin Oncol. 20:300–306. 2008. View Article : Google Scholar : PubMed/NCBI
3	Motzer RJ, Bander NH and Nanus DM: Renal-cell carcinoma. N Engl J Med. 335:865–875. 1996. View Article : Google Scholar : PubMed/NCBI
4	Itsumi M and Tatsugami K: Immunotherapy for renal cell carcinoma. Clin Dev Immunol. 2010:2845812010. View Article : Google Scholar
5	Pantuck AJ, Zisman A and Belldegrun AS: The changing natural history of renal cell carcinoma. J Urol. 166:1611–1623. 2001. View Article : Google Scholar : PubMed/NCBI
6	Singer EA, Gupta GN, Marchalik D and Srinivasan R: Evolving therapeutic targets in renal cell carcinoma. Curr Opin Oncol. 25:273–280. 2013.PubMed/NCBI
7	Yang L, Wu Q, Xu L, Zhang W, Zhu Y, Liu H, Xu J and Gu J: Increased expression of colony stimulating factor-1 is a predictor of poor prognosis in patients with clear-cell renal cell carcinoma. BMC Cancer. 15:672015. View Article : Google Scholar : PubMed/NCBI
8	Ferchichi I, Kourda N, Sassi S, Romdhane KB, Balatgi S, Cremet JY, Prigent C and Elgaaied AB: Aurora A overexpression and pVHL reduced expression are correlated with a bad kidney cancer prognosis. Dis Markers. 33:333–340. 2012. View Article : Google Scholar : PubMed/NCBI
9	Song S, Wu Z, Wang C, Liu B, Ye X, Chen J, Yang Q, Ye H, Xu B and Wang L: RCCRT1 is correlated with prognosis and promotes cell migration and invasion in renal cell carcinoma. Urology. 84(3): 7302014. View Article : Google Scholar : PubMed/NCBI
10	Pastore AL, Palleschi G, Silvestri L, Moschese D, Ricci S, Petrozza V, Carbone A and Di Carlo A: Serum and urine biomarkers for human renal cell carcinoma. Dis Markers. 2015:2514032015. View Article : Google Scholar : PubMed/NCBI
11	Vitari AC, Leong KG, Newton K, Yee C, O'Rourke K, Liu J, Phu L, Vij R, Ferrando R, Couto SS, et al: COP1 is a tumour suppressor that causes degradation of ETS transcription factors. Nature. 474:403–406. 2011. View Article : Google Scholar : PubMed/NCBI
12	Xu S, Tong M, Huang J, Zhang Y, Qiao Y, Weng W, Liu W, Wang J and Sun F: TRIB2 inhibits Wnt/β-Catenin/TCF4 signaling through its associated ubiquitin E3 ligases, β-TrCP, COP1 and Smurf1, in liver cancer cells. FEBS Lett. 588:4334–4341. 2014. View Article : Google Scholar : PubMed/NCBI
13	Sawada G, Ueo H, Matsumura T, Uchi R, Ishibashi M, Mima K, Kurashige J, Takahashi Y, Akiyoshi S, Sudo T, et al: Loss of COP1 expression determines poor prognosisin patients with gastric cancer. Oncol Rep. 30:1971–1975. 2013.PubMed/NCBI
14	Ouyang M, Wang H, Ma J, Lü W, Li J, Yao C, Chang G, Bi J, Wang S and Wang W: COP1, the negative regulator of ETV1, influences prognosis in triple-negative breast cancer. BMC Cancer. 15:1322015. View Article : Google Scholar : PubMed/NCBI
15	Shao J, Teng Y, Padia R, Hong S, Noh H, Xie X, Mumm JS, Dong Z, Ding HF, Cowell J, et al: COP1 and GSK3β cooperate to promote c-Jun degradation and inhibit breast cancer cell tumorigenesis. Neoplasia. 15:1075–1085. 2013. View Article : Google Scholar : PubMed/NCBI
16	Wei W and Kaelin WG Jr: Good COP1 or bad COP1? In vivo veritas. J Clin Invest. 121:1263–1265. 2011. View Article : Google Scholar : PubMed/NCBI
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
18	Li Z, Tian T, Lv F, Chang Y, Wang X, Zhang L, Li X, Li L, Ma W, Wu J and Zhang M: Six1 promotes proliferation of pancreatic cancer cells via upregulation of cyclin D1 expression. PLoS One. 8:e592032013. View Article : Google Scholar : PubMed/NCBI
19	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar : PubMed/NCBI
20	Marine JC: Spotlight on the role of COP1 in tumorigenesis. Nat Rev Cancer. 12:455–464. 2012. View Article : Google Scholar : PubMed/NCBI
21	Papoutsopoulou S and Janknecht R: Phosphorylation of ETS transcription factor ER81 in a complex with its coactivators CREB-binding protein and p300. Mol Cell Biol. 20:7300–7310. 2000. View Article : Google Scholar : PubMed/NCBI
22	Murphy G, Cockett MI, Ward RV and Docherty AJ: Matrix metalloproteinase degradation of elastin, type IV collagen and proteoglycan. A quantitative comparison of the activities of 95 kDa and 72 kDa gelatinases, stromelysins-1 and -2 and punctuated metalloproteinase (PUMP). Biochem J. 277:277–279. 1991. View Article : Google Scholar : PubMed/NCBI
23	Sires UI, Murphy G, Baragi VM, Fliszar CJ, Welgus HG and Senior RM: Matrilysin is much more efficient than other matrix metalloproteinases in the proteolytic inactivation of alpha 1-anti-trypsin. Biochem Biophys Res Commun. 204:613–620. 1994. View Article : Google Scholar : PubMed/NCBI
24	Adachi Y, Yamamoto H, Itoh F, Arimura Y, Nishi M, Endo T and Imai K: Clinicopathologic and prognostic significance of matrilysin expression at the invasive front in human colorectal cancers. Int J Cancer. 95:290–294. 2001. View Article : Google Scholar : PubMed/NCBI
25	Tanimoto H, Underwood LJ, Shigemasa K, Parmley TH, Wang Y, Yan Y, Clarke J and O'Brien TJ: The matrix metalloprotease pump-1 (MMP-7, Matrilysin): A candidate marker/target for ovarian cancer detection and treatment. Tumour Biol. 20:88–98. 1999. View Article : Google Scholar : PubMed/NCBI
26	Yamamoto H, Itoh F, Iku S, Adachi Y, Fukushima H, Sasaki S, Mukaiya M, Hirata K and Imai K: Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human pancreatic adenocarcinomas: Clinicopathologic and prognostic significance of matrilysin expression. J Clin Oncol. 19:1118–1127. 2001.PubMed/NCBI
27	Sumi T, Nakatani T, Yoshida H, Hyun Y, Yasui T, Matsumoto Y, Nakagawa E, Sugimura K, Kawashima H and Ishiko O: Expression of matrix metalloproteinases 7 and 2 in human renal cell carcinoma. Oncol Rep. 10:567–570. 2003.PubMed/NCBI
28	Rahim S, Minas T, Hong SH, Justvig S, Çelik H, Kont YS, Han J, Kallarakal AT, Kong Y, Rudek MA, et al: A small molecule inhibitor of ETV1, YK-4-279, prevents prostate cancer growth and metastasis in a mouse xenograft model. PLoS ONE. 9:e1142602014. View Article : Google Scholar : PubMed/NCBI